Skip to content
Our 2022 Year in Review is now live.
  • Insights

      Weekly Bulletin

      Your weekly recap of news and analysis from the psychedelic sector.

      Read the Latest

      Research Review

      A monthly review of the most important psychedelics research.

      Review Archive

      News & Interviews

      The latest news from across the psychedelics space.

      Explore Now
  • Data

      Psychedelics Patent Trackers

      We track the latest patents and filings related to psilocybin, MDMA and DMT.

      Psilocybin Patents
      Psilocybin Patent Filings
      LSD Patents
      MDMA Patents
      DMT Patents
      Psilocybin Patents
      Psilocybin Patent Filings
      LSD Patents
      MDMA Patents
      DMT Patents

      Psychedelic Legalization & Decriminalization Tracker

      Mapping psychedelic drug policy reform across the United States

      Explore the Tracker
      New: Oregon Local Jurisdiction Tracker

      Psychedelics Drug Development Tracker

      From drug discovery to regulatory approval, we map drug development in psychedelics.

      Explore the Tracker
  • Companies

      Stocks & Companies Directory

      A directory of all the major psychedelics stocks, companies and ETFs.

      Access Directory

      Sector Landscape Map

      Explore the Psychedelic Sector Landscape visually using our new tool.

      Explore Now

      Stock Watchlist

      A one-stop overview of psychedelics stocks financial performance.

      Explore Now
  • Psychedelic Careers
  • Contact
Search
Close
Read more about the article MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

  • Post published:August 25, 2022
  • Post category:Press Release
Read more about the article MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

  • Post published:April 14, 2022
  • Post category:Press Release
Read more about the article MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

  • Post published:April 5, 2022
  • Post category:Press Release
Read more about the article MindMed Reports Full Year 2021 Financial Results and Business Highlights

MindMed Reports Full Year 2021 Financial Results and Business Highlights

  • Post published:March 28, 2022
  • Post category:Press Release
Read more about the article MindMed Announces Transition of CFO

MindMed Announces Transition of CFO

  • Post published:March 25, 2022
  • Post category:Press Release
Read more about the article MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

  • Post published:February 23, 2022
  • Post category:Press Release
Read more about the article FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

  • Post published:January 25, 2022
  • Post category:Press Release
Read more about the article MindMed Enrolls First Participant in a Study of its Session Monitoring System

MindMed Enrolls First Participant in a Study of its Session Monitoring System

  • Post published:January 18, 2022
  • Post category:Press Release
Read more about the article Stephen Hurst Resigns from MindMed Board of Directors

Stephen Hurst Resigns from MindMed Board of Directors

  • Post published:January 7, 2022
  • Post category:Press Release
Read more about the article MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

  • Post published:January 4, 2022
  • Post category:Press Release

End of content

No more pages to load

Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Psychedelic Stocks and Companies
  • News & Interviews
  • Psychedelic Sector Jobs
  • Data Bank

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

  • Psychedelic Alpha © 2022, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.